France Fertility Services Market Overview,2030

The fertility service industry in France has experienced consistent growth under its publicly funded healthcare framework, emphasizing fair access to assisted reproductive technologies (ART). Public financing is crucial, with the national health insurance offering coverage for up to four IVF cycles for qualified women who are under 43, as well as for donor sperm services. This system has facilitated wide access to ART, especially for heterosexual couples, and more recently, for single women and lesbian couples after changes in the 2021 bioethics legislation. IVF was introduced in France during the 1980s, but its development was influenced by strict rules regarding donor anonymity, which historically barred children conceived through donation from obtaining identifying details about their biological donors. However, starting in September 2022, France officially abolished donor anonymity, allowing individuals conceived via donation to seek both identifying and non-identifying information once they reach adulthood. In France, ART encompasses several procedures, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), gamete donation, and embryo transfer. These treatments are governed by national bioethics regulations and provided through a network of public hospitals and licensed private clinics. ART facilitates conception for cases involving medical infertility, genetic concerns, or diverse family structures, and is increasingly aided by modern laboratory techniques. French research and development initiatives aim to enhance embryo viability and the efficiency of procedures. Vitrification, a fast cryopreservation technique, has become the standard for freezing eggs and embryos, yielding improved survival rates and flexibility in treatment schedules. Emerging technologies, such as DaVitri, automate the vitrification process to minimize variability among operators and enhance consistency. Furthermore, embryo diagnostics, including preimplantation genetic testing (PGT), are progressing, albeit under strict regulations. These advancements, together with France's ethical governance and public funding, establish the nation as a frontrunner in providing inclusive and medically sound fertility care.

According to the research report, ""France Fertility Service Market Overview, 2030,"" published by Bonafide Research, the France Fertility Service market is anticipated to grow at 8.64% CAGR from 2025 to 2030. This growth is influenced by changes in demographics, postponed parenthood, and an increase in legal access to assisted reproductive technologies (ART). A significant reform took place in 2021, with full implementation expected by 2025, which broadened IVF and other ART services to single women and LGBTQ+ people, representing a critical change in reproductive rights and inclusion. According to the updated bioethics law, public health insurance now covers up to four IVF cycles for women who are under 43 years old, irrespective of their marital status or sexual orientation. This aligns France with wider European guidelines and diminishes the need for seeking fertility care across borders.Key participants in this sector consist of Groupe BioSanté, which combines research with clinical offerings, along with various hospital-based ART facilities like those connected to CHU de Nantes and Hôpital Cochin. These centers provide services like IVF, ICSI, donor sperm options, and fertility preservation, often working within collaborative frameworks that include endocrinology, genetics, and reproductive advice. There is also a growing interest in donor gamete services, particularly in sperm donation, due to the implementation of donor identity disclosure rights taking effect in 2025. From March 31, 2025, only gametes from donors who agree to identity disclosure can be utilized, promoting transparency and ethical standards in line with the new bioethics legislation. Oversight is managed by the Agence de la biomédecine, which handles donor databases, accredits ART centers, and ensures compliance with national and EU regulations. The legislation bans surrogacy and paid gamete donations but encourages altruistic donation, requiring informed consent, traceability, and fair access.

The fertility services in France by procedure is divided into IVF with ICSI, IUI, IVF without ICSI, Surrogacy and Others In France, the most common type of assisted reproductive technology (ART) is IVF combined with intracytoplasmic sperm injection (ICSI). This popularity is mainly due to its effectiveness in clinical settings and its alignment with the country’s strict guidelines regarding embryo transfers. Within the national health coverage framework, women under 43 who qualify can receive public support for up to four IVF cycles, with ICSI typically offered, especially in situations involving male infertility or previous fertilization issues. Intrauterine insemination (IUI) is generally the initial treatment choice, especially for couples with mild fertility challenges or for same-sex female couples, and it is also financially supported by the state. IVF that does not involve ICSI is used to a moderate extent, generally for couples with optimal sperm quality and no history of fertilization failure, but its use has decreased as ICSI has become the norm. Surrogacy is illegal in France as stated in Article 16-7 of the Civil Code, which bans all kinds of surrogacy, whether commercial or altruistic. Nonetheless, a ruling from the Supreme Court in 2024 has allowed French citizens to have their legal parentage recognized for children born through surrogacy arrangements abroad if specific legal criteria are fulfilled. This change represents a major development in legal acknowledgment, but surrogacy within the country remains prohibited. Services involving donor gametes are readily accessible and are seeing increased usage. Following the introduction of the bioethics law in 2021, which will be fully enacted by 2025, the practice of donor anonymity has been removed.


In France fertility service by cause of infertility is divided into Male Infertility and Female Infertility. In France, the most frequently reported reproductive issue is female infertility, heavily influenced by age and lifestyle choices. As women tend to postpone having children into their 30s and 40s due to career goals, financial considerations, and changing societal expectations the age for optimal fertility decreases. Research indicates that the likelihood of becoming pregnant falls from 85% at the age of 25 to under 45% by the age of 40. Factors related to age are worsened by lifestyle choices such as stress, unhealthy eating, smoking, and exposure to chemicals that disrupt hormonal functions, which can impact ovulation and hormone levels. Health issues like endometriosis and polycystic ovary syndrome (PCOS) are also more common in women looking for fertility assistance, often needing advanced treatments like IVF or ovulation stimulation. Male infertility, which was once not widely acknowledged, is now increasing steadily throughout France and accounts for almost half of all infertility cases. The causes include various factors from decreased sperm count and movement to imbalances in hormones and genetics. City living, characterized by lack of physical activity, obesity, alcohol intake, and environmental toxins, has been associated with decreasing sperm quality. Between 1973 and 2011, sperm concentration in men fell by nearly 50%, continuing to raise concerns about public health. The indicating a growing need for diagnostic tools, hormone treatments, and assisted reproductive technologies like ICSI. These developments highlight a changing reproductive environment in France, where both female and male infertility are influenced by age, lifestyle, and environmental factors. To tackle these challenges, there is a need for not only medical advancements but also public awareness, prompt action, and comprehensive policies that promote various family-building options within the framework of France’s changing bioethics.

The France fertility service by end user is divided into Fertility Clinics, Hospitals, Surgical Centers and Clinical Research Institutes. Facilities such as CHU de Nantes and Hôpital Cochin deliver government-funded IVF, ICSI, and donor gamete options, ensuring that women under 43 have fair access. ART services are part of comprehensive care pathways, often merging endocrinology with gynecology and reproductive counseling. Regional Health Agencies (ARS) oversee the provision and financing of these services, reinforcing France’s dedication to universal reproductive healthcare.Private fertility clinics, mainly found in major cities like Paris, Lyon, and Marseille, supplement the public sector with reduced waiting times and a wider range of services. Institutions such as Institut Médical de Fertilité and Inovie Fertilité create tailored treatment plans, provide sophisticated diagnostic tools, and offer options for preserving fertility, serving both local and international patients. These clinics generally operate under strict accreditation from the Agence de la biomédecine and comply with national bioethics regulations, which cover donor identity, embryo management, and gamete tracking.Surgical centers, usually part of university hospitals or specialized gynecological facilities, carry out procedures related to infertility such as fibroid excision, endometriosis surgery, and tubal operations. These procedures are essential for enhancing natural fertility or improving outcomes from ART, and they increasingly utilize minimally invasive methods along with comprehensive postoperative care.On the research front, INSERM (Institut National de la Santé et de la Recherche Médicale) is crucial in propelling advancements in ART. Through initiatives like Impact Santé and Technology Research Accelerators, INSERM investigates embryo diagnostics, cryopreservation, and AI-assisted fertility solutions. Its interdisciplinary approach connects basic research with clinical use, influencing national policies and fostering innovation. Collectively, France’s public hospitals, private clinics, surgical units, and research organizations create a holistic, ethically responsible fertility framework that emphasizes accessibility, quality, and scientific advancement.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Fertility Services Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Procedure
• IVF with ICSI
• IUI
• IVF without ICSI
• Surrogacy
• Others

By Service
• Fresh Non-Donor
• Frozen Non-Donor
• Egg and Embryo Banking
• Fresh Donor
• Frozen Donor
By Cause of Infertility
• Male Infertility
• Female Infertility

By End User
• Fertility Clinics
• Hospitals
• Surgical Centers
• Clinical Research Institutes
Show more